Chondroitin sulfate - Alcon

Drug Profile

Chondroitin sulfate - Alcon

Alternative Names: Chondroitin 6-sulfate sodium - Alcon; Chondroitin 6-sulfate sodium - Nestle; Chondroitin sulfate - Nestle; Chondroitin sulphate - Alcon; Chondroitin sulphate - Nestle; Lacrypos

Latest Information Update: 27 Aug 2010

Price : $50

At a glance

  • Originator Alcon
  • Class Anti-inflammatories; Antirheumatics; Glycosaminoglycans
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Dry eyes; Eye disorders

Most Recent Events

  • 26 Aug 2010 Alcon has been acquired by Novartis
  • 22 Jan 1999 Launched for Dry eyes in Belgium (Ophthalmic)
  • 22 Jan 1999 Launched for Dry eyes in Switzerland (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top